THE GROWTH of subcutaneous isogeneic transplants of a variety of mouse tumours has been shown to be inhibited by both systemic (Woodruff and Boak, 1966; Woodruff and Dunbar, 1973) and local (Likhite and Halpern, 1974; Scott, 1974; Woodruff and Dunbar, 1975) administration of killed vaccines of certain anaerobic corynebacteria and propionibacteria. The present investigation was undertaken to determine whether the growth of intracerebral transplants of one such tumour could be similarly inhibited by systemic or local administration of an active strain of Corynebacterium parvum, either alone or in combination with active specific immunotherapy, partial surgical excision or radiotherapy.
Mice. Adult (18-22 g) female CBA/Ca mice were used throughout.
Tumour.-The tumour (WI) was originally induced in a female CBA/Ca mouse with methylcholanthrene. It was stored in liquid N2 after 15 transplant generations, and was transplanted once more before being used in the experiments. Cell suspensions were prepared with pronase, as previously described (Woodruff and Boak, 1966) . The final suspension in Dulbecco's solution contained 106 viable cells and not more than 2 x 104 non-viable cells per ml. A suspension of 0-01 ml (104 viable cells) was injected under ether anaesthesia into the right cerebral hemisphere through a 25-gauge needle with a micrometer syringe. The needle, which was inserted through the right calvarium, was provided with a plastic stop which limited its penetration to 4 mm.
Irradiation.-Tumour cells were irradiated in Petri dishes, using a Westinghouse 250 kV X-ray machine. The total dose was 22,000 rad at a dose rate of 274 rad/min.
Mice were given 500 rad local irradiation to the head with the same machine, at a dose rate of 59-6 rad/min, using a special container (Fig. 1) provided with lead shielding (minimum thickness 10 mm) which reduced the dose of irradiation to the rest of the animal to less than 0-5 rad.
Partial excision of tumour.-A small linear incision was made in the scalp on the right side and the thin calvarium exposed. A sharp-pointed scalpel was inserted through bone and brain in a circumferential fashion around the site of the previous injection. A core of tissue including bone, brain and tumour was excised. A single suture was inserted through the skin.
Corynebacteria.-A formalin-killed suspension of C. acnes strain CN6134 (commonly called C. parvum) was used throughout, except in one group of mice (Group 15) in which a formalin-killed suspension of Propionibacterium freudenreichii strain NTC/10470 was used instead, as a control. This organism has little or no antitumour activity when given systemically (McBride, et al., 1975 01 ml. For intracerebral injection at the site of tumour inoculation, the same suspension was used when the dose was 0 07 mg: when the dose was 02 mg, the suspension was concentrated so that the volume injected was still 0.1 ml.
Dexamethasone.-The mice in some groups were given repeated injections of dexamethasone (Decadron; Merck, Sharp & Dohme) with the object of reducing the incidence of cerebral oedema.
A series of experiments was set up, each comprising one group of untreated controls and several groups of treated mice. There were 6 mice in each group.
As there was no significant difference in the survival of control mice in different experiments, the results have been pooled and set out in a single table (Table I) .
Intracerebral tumour inoculation was well tolerated. Growing tumours gradually eroded the vault of the skull, and after about 2 weeks untreated mice began to lose weight, but showed no evidence of pain. Three animals which had developed hind limb paralysis were killed, and at autopsy they were found to have extensive intracerebral tumours.
The results of treatment were as follows:
1. Partial excision of the tumour on Day + 9 did not prolong survival.
2. Local irradiation prolonged survival if given on Day + 3, but was ineffective if given later (Day + 7).
3. The effect of dexamethasone was erratic but survival was prolonged in some mice. The comparative effectiveness of the various immunotherapeutic procedures is summarized in Table II. The response of intracerebral transplants of an immunogeneic tumour to systemic or local administration of C. parvum appears from these results to be similar to that of subcutaneous transplants, though with intracerebral transplants, systemic treatment had to be given before tumour inoculation, and the dose which could be given locally was limited by toxicity. It was thought that the toxic manifestations resulted from cerebral oedema, and it was therefore expected that administration of dexamethasone would improve the situation. This prediction was not confirmed, but this may have been because the drug was given only twice daily or for too short a time. The hypothesis of cerebral oedema cannot therefore be excluded and still seems the most likely explanation of the toxicity.
It has been reported that contact inhibition of the growth of s.c. tumour transplants by BCG (i.e. inhibition when BCG is mixed with the tumour inoculum) is not T-cell dependent (Moore, Lawrence and Nisbet, 1976: Pimm and Baldwin, 1976) and probably results from local mobilization and activation of macrophages, and the same is true of contact inhibition of s.c. tumours by C. parvum (Woodruff and Whitehead, unpublished it is just conceivable that this is true also of the response to local injection of C. parvum after tumour inoculation, despite the fact that in the case of s.c. transplants their response has been found to be highly T-cell-dependent (Scott, 1974; Woodruff and Dunbar, 1975; Woodruff and Warner, 1977) . The dramatic response of intracerebral transplants to s.c. injection of C. parvum mixed with irradiated tumour cells would seem to imply, however, that such transplants are subject to inhibition as the result of a specific immunological reaction. This is scarcely surprising, for it has long been known (Woodruff, 1960) that the status of the brain as an immunologically privileged site is by no means absolute, and is lost in the case of transplants which grow and become vascularized quickly.
The results raise the question whether it would be justifiable to set up a pilot study of local and systemic administration of C. parvum, as an addition to surgical resection, in patients with cerebral malignant gliomas. The extent to which the clinical therapeutic response would reflect that seen in the animal model is unpredictable. The main risk, especially with local administration of C. parvum, would probably be cerebral oedema. Provided the dose of C. parvum is kept low, however, control by standard procedures should not prove unduly difficult in patients in whom a bone flap is raised to provide surgical access.
